Allogeneic HSCT was recommended for patients in first CR with matched (related or unrelated) donor, except patients with core-binding factor AML or with normal karyotype and either NPM1+/FLT3-ITDwt or CEBPA+AML. Here, FLT3 is linked to acute myeloid leukemia.